The global postpartum depression drugs market is anticipated to reach USD 1.59 billion by 2030 and is expected to expand at a CAGR of 9.63% during the forecast period. The increasing number of pregnancies worldwide primarily drives market growth. Many women suffer from postpartum depression (PPD) after having a baby and are at high risk of developing major depression later in life. According to the Cleveland Clinic Estimate, postpartum depression is a common condition that affects 1 in 7 women after giving birth to a child. Thus, rising government support for women who had childbirth and are suffering from mood disorders like PDD is expected to boost demand for drugs over the forecast period.
According to the Indian Association of Preventive & Social Medicine, every year, around 30 million women experience pregnancy, and 27 million women have live childbirths. In July 2022, the Government of India launched several schemes to support pregnant women, such as Janani Suraksha Yojana (JSY) and Janani Shishu Suraksha Karyakaram (JSSK). Under these programs, the government offers free of cost treatment related to pregnancy, such as diagnostics, medicines, and other consumables. Thus, initiatives like JSSK and JSY support women in completing treatment such as postpartum depression, simultaneously driving market growth during the forecast period.
Another significant factor driving the adoption of postpartum depression drugs is rising healthcare expenditures, which help to improve infrastructure and improve patient access to healthcare facilities. According to the PETERSON-KFF Health System Tracker report, women spend around USD 18,865 annually on pregnancy, childbirth, and postpartum treatment. There is significant variation. around this, spending and costs vary significantly by region worldwide. The increasing access of women to PPD drug treatment is anticipated to drive market growth in the coming years.
This product will be delivered within 1-3 business days.
According to the Indian Association of Preventive & Social Medicine, every year, around 30 million women experience pregnancy, and 27 million women have live childbirths. In July 2022, the Government of India launched several schemes to support pregnant women, such as Janani Suraksha Yojana (JSY) and Janani Shishu Suraksha Karyakaram (JSSK). Under these programs, the government offers free of cost treatment related to pregnancy, such as diagnostics, medicines, and other consumables. Thus, initiatives like JSSK and JSY support women in completing treatment such as postpartum depression, simultaneously driving market growth during the forecast period.
Another significant factor driving the adoption of postpartum depression drugs is rising healthcare expenditures, which help to improve infrastructure and improve patient access to healthcare facilities. According to the PETERSON-KFF Health System Tracker report, women spend around USD 18,865 annually on pregnancy, childbirth, and postpartum treatment. There is significant variation. around this, spending and costs vary significantly by region worldwide. The increasing access of women to PPD drug treatment is anticipated to drive market growth in the coming years.
Postpartum Depression Drugs Market Report Highlights
- The postpartum anxiety segment held the largest share of the market in 2023. This can be attributed to the disease's high treatment rate and growing prevalence in developed and developing countries.
- Based on the treatment type, the hormonal therapy segment is expected to grow at the fastest CAGR during the forecast period. This can be attributed to the development and commercialization of new hormonal drugs and increased adoption by smaller hospitals and facilities for the treatment of PDD.
- In 2023, the oral segment held the largest share of the market based on the route of administration. This dominance can be attributed to the increase in the prevalence and incidence of disease worldwide, the large availability of products, and the rising demand for new generic oral drugs for treatment.
- The hospital pharmacy segment held the largest share of the market based on distribution channels in 2023. Hospital treatment rates, patient preference for hospitals over other healthcare settings for PDD treatment, and the increasing number of patients visiting hospitals.
- North America dominated the market owing to factors such as advanced healthcare infrastructure, rising disease prevalence, and favorable regulatory environment.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Postpartum Depression Drugs Market Variables, Trends & Scope
Chapter 4. Postpartum Depression Drugs Market: Treatment Estimates & Trend Analysis
Chapter 5. Postpartum Depression Drugs Market: Treatment Estimates & Trend Analysis
Chapter 6. Postpartum Depression Drugs Market: Route of Administration Estimates & Trend Analysis
Chapter 7. Postpartum Depression Drugs Market: Distribution Channel Estimates & Trend Analysis
Chapter 8. Postpartum Depression Drugs Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Sage Therapeutics, Inc.
- Pfizer Inc.
- Eli Lilly and Company.
- GSK plc
- Merck & Co., Inc.
- Biogen Inc.
- Bausch Health Companies Inc.
- Cipla Inc.
- Novartis AG.
- Teva Pharmaceutical Industries Ltd.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 120 |
Published | June 2024 |
Forecast Period | 2023 - 2030 |
Estimated Market Value ( USD | $ 838.4 Million |
Forecasted Market Value ( USD | $ 1590 Million |
Compound Annual Growth Rate | 9.6% |
Regions Covered | Global |
No. of Companies Mentioned | 10 |